Clinical trials: Girls
Coronary Artery Disease, Renal Impairment
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the…
- Trial name
- NCT00209430
- Testing
- Iodixanol 320 mgI/mL
- Where
- Sweden
- Volunteers
- 408 people
- Sponsor
- GE Healthcare
Pelvic Inflammatory Disease
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845 using a placebo controlled, randomized, single…
- Trial name
- NCT03054402
- Testing
- BAY1834845
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Bayer
Human Papillomavirus
Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening
A prospective multicenter interventional study will be conducted to enroll women undergoing routine cervical cancer screening to collect cervical liquid-based cytology (LBC) specimen(s).
- Trial name
- NCT04746872
- Testing
- Alinity m HR HPV
- Where
- 63 sites in United States
- Volunteers
- 14,935 people
- Sponsor
- Abbott Molecular
Overactive Bladder, Benign Prostate Hyperplasia
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
- Conditions
- Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate, Photoselective Vaporization Prostatectomy
- Trial name
- POST-TURP (NCT01747577)
- Testing
- Solifenacin Succinate
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Astellas Pharma Korea, Inc.
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06469281
- Testing
- 27T51, Cemiplimab, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Regeneron Pharmaceuticals
Vulvovaginal Candidiasis
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
The purpose of this study is to evaluate the efficacy and safety of different doses of Venus association in the treatment of vulvovaginal candidiasis.
- Trial name
- NCT05031481
- Testing
- Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4
- Sponsor
- EMS
Diabetes Mellitus
Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
- Trial name
- NCT04905628
- Testing
- Dexcom CGM System
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- DexCom, Inc.
Postpartum Depression
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
The primary purpose of this study was to evaluate whether the safe-use conditions for administration of brexanolone (ZULRESSO®) can be implemented in a home setting.
- Trial name
- NCT05059600
- Testing
- ZULRESSO®
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Intra-abdominal Infections
A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.
- Trial name
- NCT01473836
- Testing
- Metronidazole, Ceftriaxone sodium
- Where
- 15 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Pfizer
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Pregnant Women
Effects of Chinese Medicine on Early Pregnant Women
From April 2021 to December 2021, 45 pregnant women who received intro fertilization-embyro transfer (IVF-ET) were recuited. According to their own wishes, 28 of them took Chinese medicine from the 2nd week after embryo transfer…
- Trial name
- NCT04848571
- Testing
- Fetal Protection Pill
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Meiji Health Science and Technology Co., Ltd.
Ovarian Cancer
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone
- Trial name
- NGR018 (NCT01358071)
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 8 sites in Italy, United Kingdom
- Volunteers
- 119 people
- Sponsor
- AGC Biologics S.p.A.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
IgA Nephropathy
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA…
- Trial name
- NCT04905212
- Testing
- Telitacicept 160mg, Telitacicept 240mg
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- RemeGen Co., Ltd.
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
Researchers are looking for a better way to treat vasomotor symptoms, a condition of having hot flashes. The condition is caused by hormonal changes and occurs primarily in women, but can also affect men.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05481528
- Testing
- Moxifloxacin, Elinzanetant (BAY3427080)
- Where
- Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bayer
Postmenopausal, Healthy Adult Female Participants
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
- Trial name
- LAE102 (NCT06908707)
- Testing
- LAE102 SC, LAE102 IV
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Acute Kidney Injury, Renal Insufficiency
A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney Function
The main purpose of this study is to investigate how reliable a test assessing the renal functional reserve (RFR) and the maximum glomerular filtration rate (maxGFR) are.
- Trial name
- NCT07368712
- Testing
- No investigational study intervention
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.